Across multiple cancer types (Figure 4—figure supplement 2), we observed that in lung cancer cells with wild-type p53, high GMCL1 expression combined with low 53BP1 levels was associated with significantly increased resistance to cabazitaxel and paclitaxel compared with cells showing low GMCL1 expression and high 53BP1 levels (Figure 4C). The gene discussed is TP53BP1; the disease is lung carcinoma.